Pine Bark Extract: The Definitive Guide

What is pine bark extract?

Pine bark extract is a polyphenol-rich material made from bark of Pinus species. Pycnogenol is a trademarked extract from French maritime pine (Pinus pinaster subsp. atlantica) standardized largely by its procyanidin content. Enzogenol and other pine extracts are separate preparations.

A branded ingredient can improve product traceability, but it does not guarantee that every marketed claim is proven. Species, bark source, extraction, marker assay and co-ingredients still matter.

Typical Pine Bark Extract Protocols

No RDA, AI or UL exists for pine bark extract. Research schedules should not be converted into a universal consumer regimen.

Species and product

Record the Latin species and branded or generic extract. Pycnogenol, Enzogenol and unspecified pine bark are not interchangeable.

Per-dose amount

Arcangeli used 100 mg three times daily, not a single 300 mg administration.

Condition

Keep venous symptoms, blood pressure, diabetes, osteoarthritis and cognition as separate evidence questions.

Comparator

Compression, placebo and usual care answer different questions. Do not merge them without preserving the comparison.

What is pine bark extract commonly used for?

Products are marketed for circulation, chronic venous insufficiency, blood pressure, glucose, joints, cognition, erectile function, skin and exercise. This breadth is itself a reason to slow down: evidence for one condition does not validate another.

The Cochrane review found only one or a few small studies for most disorders, inconsistent outcome measures and poor reporting. Its authors could not reach definitive conclusions. [1]

Which forms and labels matter?

Look for species, plant part, extract name, procyanidin standardization method, amount per capsule and serving size. A blend containing pine bark plus arginine, Centella asiatica or other ingredients cannot establish a pine-bark-only effect.

What does the human evidence show?

The 2020 Cochrane update included 27 randomized trials with 1,641 participants across asthma, ADHD, cardiovascular conditions and risk factors, chronic venous insufficiency, diabetes, erectile and female sexual dysfunction, osteoarthritis, osteopenia and traumatic brain injury. Twenty-four studies used placebo, yet only four trials had low overall risk of bias; 22 were unclear and one was high risk. Outcomes usually could not be pooled. For the condition-level comparisons described, certainty was very low, and serious adverse events and hospital admissions were often not reported. [1]

Arcangeli randomized 40 adults with chronic venous insufficiency and varicose veins to Pycnogenol 100 mg three times daily or placebo for two months. Edema, heaviness and pain scores improved, while Doppler-assessed venous blood flow did not. The result belongs to a small early study of one named product, not to every cause of leg swelling. [2]

Malekahmadi and colleagues pooled 24 randomized trials with 1,594 participants. Estimates favored Pycnogenol for fasting glucose, HbA1c, systolic and diastolic pressure, BMI, LDL and HDL. The average pressure changes were modest, and heterogeneous trials of surrogate markers cannot prove fewer cardiovascular events. [3]

How might pine bark extract work?

Pine bark extracts contain procyanidins, catechin, epicatechin and taxifolin-related compounds. Laboratory studies suggest effects on oxidation, endothelial signaling, inflammation and extracellular matrix. Absorption and microbial metabolism vary substantially. Mechanistic plausibility does not resolve the very low certainty of condition-specific clinical evidence.

What are the risks and interactions?

Reported effects include gastrointestinal upset, headache, dizziness, mouth discomfort and skin reactions. The evidence base is too small and inconsistently reported to define uncommon or long-term harms.

Potential additive effects matter with anticoagulants, antiplatelet drugs, antihypertensives and glucose-lowering medicines. Immune effects are also plausible, so transplant recipients and people using immunosuppressants should seek specialist review. Surgery, unexplained bleeding, fainting or symptomatic low glucose require clinical guidance.

Pregnancy, breastfeeding and pediatric use lack adequate general safety evidence. A pine or excipient allergy is relevant.

Legal status in the United States and Canada

In the United States, pine bark extracts are dietary supplements, not approved treatments for venous disease, hypertension, diabetes or other chronic disorders.

In Canada, licensed natural health products carry product-specific conditions. A licence does not make generic bark equivalent to the named trial material.

What should be monitored?

Record species, extract, procyanidin claim, dose per administration, frequency, co-ingredients, symptoms, validated measurements and medicine changes. New one-sided swelling, chest pain, breathlessness or a hot painful leg needs prompt assessment rather than supplement experimentation.

What happens after stopping?

No withdrawal syndrome or standard taper has been established. Continue prescribed treatment and discuss changes when the supplement is used alongside blood-pressure, glucose or vascular care.

How should it be stored?

Keep it dry in the original closed container, preserve the lot and expiry information and follow the product label. Store away from children.

Community experiences

Anecdotes often combine several conditions and omit product identity, comparator and measurement method. They can suggest tracking fields but cannot determine whether swelling is benign or whether a supplement caused a change.

How does pine bark extract compare with other approaches?

Compression and evaluation of chronic venous insufficiency have different evidence and safety roles from a supplement. Established blood-pressure and diabetes care use validated targets and outcome data. Pine bark research largely concerns short surrogate outcomes and should remain adjunctive to appropriate assessment.

Frequently asked questions

Is Pycnogenol the same as pine bark extract?

It is one named French maritime pine bark extract. Other species and extracts are not automatically equivalent.

What did the 2020 Cochrane review conclude?

Small samples, few trials per condition, varied outcomes and poor reporting prevented definitive efficacy or safety conclusions. [1]

What schedule did the venous-insufficiency trial use?

Pycnogenol 100 mg three times daily for two months. [2]

Did that trial improve venous blood flow?

No Doppler blood-flow effect was observed, despite improvements in symptom scores. [2]

Do pooled blood-pressure results prove cardiovascular protection?

No. Small changes in a surrogate marker do not establish fewer heart attacks or strokes.

Can pine bark be combined with blood thinners?

The exact product and bleeding context need clinician or pharmacist review.

Glossary

Terms used in this guide.

Pycnogenol

A trademarked standardized extract from French maritime pine bark.

Procyanidins

Polyphenolic compounds used as major constituents and standardization markers in some pine bark extracts.

Chronic venous insufficiency

Impaired return of blood through leg veins, which can cause swelling, heaviness and skin changes.

Certainty of evidence

Confidence that an estimated effect is close to the true effect.

Surrogate endpoint

A measurement used in place of a direct clinical outcome.

Crossover trial

A trial in which participants receive more than one intervention in sequence.

How this guide was researched

This draft anchors conclusions to the current 2020 Cochrane update, then adds an exact early venous protocol and a cardiometabolic meta-analysis. It does not use a manufacturer-authored narrative review to grade efficacy. Evidence was updated October 9, 2026.

How this guide was made

The ledger preserves product, amount per administration, frequency, condition, comparator, duration, outcome, access level and correction status.

Sources

Related guides